Complete the DUDIT screening questionnaire to identify hazardous drug use, harmful use, and potential drug dependence. 11-item validated assessment.
The Drug Use Disorders Identification Test (DUDIT) is an 11-item self-report screening instrument developed by Berman et al. (2005) to identify individuals with drug-related problems, including hazardous use, harmful use, and drug dependence. It is the drug-use parallel to the widely-used AUDIT (Alcohol Use Disorders Identification Test) and has been validated across multiple clinical populations and cultural settings.
The DUDIT covers three domains: drug use frequency and amount (questions 1–4), drug dependence symptoms (questions 5–9), and drug-related problems and harm (questions 10–11). Scoring ranges from 0 to 44, with gender-specific cutoffs — men scoring ≥6 and women scoring ≥2 likely have drug-related problems, while scores ≥25 for either sex suggest drug dependence requiring comprehensive assessment.
This screening tool is widely used in primary care, emergency departments, substance abuse treatment programs, criminal justice settings, and employee assistance programs. A positive screen should always be followed by a thorough clinical assessment — the DUDIT identifies risk but does not diagnose specific substance use disorders. The tool addresses all illicit substances and misuse of prescription medications.
Early identification of drug use problems enables timely intervention before consequences worsen. The DUDIT provides a standardized, validated screening approach that can be administered in under 5 minutes. Its domain structure (frequency, dependence, harm) helps clinicians understand the nature and severity of drug use problems and tailor their response accordingly.
DUDIT Score = Sum of all 11 items Questions 1–9: scored 0–4 (Never to Daily/Almost Daily) Questions 10–11: scored 0, 2, or 4 (No / Yes but not this year / Yes this year) Maximum score: 44 Cutoffs: • Men: ≥6 = probable drug-related problems; ≥25 = probable dependence • Women: ≥2 = probable drug-related problems; ≥25 = probable dependence
Result: DUDIT Score: 12/44 — Hazardous/harmful drug use
Score breakdown: Frequency/Amount (Q1-4) = 6/16, Dependence (Q5-9) = 2/20, Harm (Q10-11) = 4/8. Above the male cutoff of 6, indicating probable drug-related problems. The elevated harm score (Q11: others have expressed concern) reinforces the need for brief intervention and further clinical assessment.
The DUDIT was developed by Berman et al. at the Karolinska Institute in Stockholm, Sweden, and published in 2005. It was specifically designed as the drug-use counterpart to the AUDIT alcohol screen. Validation studies across Sweden, Germany, the UK, and the US demonstrated good psychometric properties: internal consistency (Cronbach's alpha 0.80–0.93), test-retest reliability (r = 0.85), and concurrent validity with DSM-IV substance use disorder diagnoses.
The DUDIT is one of several validated drug screening instruments. The DAST-10 (Drug Abuse Screening Test) is another common screen with 10 yes/no questions. The ASSIST (Alcohol, Smoking, and Substance Involvement Screening Test) by WHO covers all substance types. Each has strengths: DUDIT parallels the AUDIT format (familiar to clinicians), DAST-10 is shorter, and ASSIST covers all substances including alcohol and tobacco in one instrument.
For scores in the hazardous range (6–24), brief interventions using motivational interviewing techniques are recommended. The FRAMES model (Feedback, Responsibility, Advice, Menu of options, Empathy, Self-efficacy) provides structure. Brief interventions show moderate effect sizes for reducing drug use in primary care settings. For scores suggesting dependence (≥25), referral to specialized substance use disorder treatment is appropriate.
The Drug Use Disorders Identification Test (DUDIT) is an 11-item screen developed by Berman, Bergman, Palmstierna, and Schlyter (2005) at the Karolinska Institute in Sweden. It was designed as a companion to the AUDIT (alcohol screen) to identify individuals with drug-related problems. It has been validated in multiple countries and clinical settings with good sensitivity and specificity.
The DUDIT covers all drugs other than alcohol, including: cannabis/marijuana, stimulants (amphetamines, cocaine, methamphetamine), opioids (heroin, fentanyl, misused prescription opioids), benzodiazepines (non-prescribed use), hallucinogens (LSD, psilocybin), inhalants, and any non-prescribed or misused prescription medication. Alcohol is covered by the separate AUDIT instrument.
Research shows women develop drug-related problems at lower consumption levels than men, likely due to differences in body composition, metabolism, and neurobiological responses. The lower female cutoff (≥2 vs. ≥6 for men) ensures adequate sensitivity for detecting drug problems in women. The dependence cutoff (≥25) is the same for both sexes.
No — the DUDIT is a screening tool that identifies individuals likely to have drug-related problems. A positive screen should be followed by comprehensive clinical assessment (using DSM-5 criteria for Substance Use Disorder) by a qualified professional. Screening tools prioritize sensitivity (catching most cases) and may produce false positives.
In primary care: annually during routine health assessments, or when clinical suspicion exists. In substance abuse treatment: at intake and periodically during treatment to track progress. In emergency departments: when drug-related presentations are suspected. Post-treatment: at follow-up visits to monitor relapse risk. The instrument is brief enough for repeated administration.
SAMHSA National Helpline: 1-800-662-4357 (free, confidential, 24/7, English/Spanish). SAMHSA Treatment Locator: findtreatment.gov. Crisis Text Line: text HOME to 741741. Narcotics Anonymous: na.org. Your primary care physician or employer's Employee Assistance Program (EAP) can also provide confidential referrals. Treatment works — most people with substance use disorders recover with appropriate support.